Details for Patent: RE44599
✉ Email this page to a colleague
Which drugs does patent RE44599 protect, and when does it expire?
Patent RE44599 protects ZYDELIG and is included in one NDA.
This patent has forty-six patent family members in twenty countries.
Summary for Patent: RE44599
Title: | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Abstract: | Compounds that inhibit P13K.delta. activity, including compounds that selectively inhibit P13K.delta. activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K.delta. plays a role in leukocyte function, using the compounds also are disclosed. |
Inventor(s): | Fowler; Kerry W. (Seattle, WA), Huang; Danwen (Sammamish, WA), Kesicki; Edward A. (Bothell, WA), Ooi; Hua Chee (Kirkland, WA), Oliver; Amy (Bothell, WA), Ruan; Fuqiang (Bellevue, WA), Treiberg; Jennifer (Redmond, WA), Puri; Kamal Deep (Lynnwood, WA) |
Assignee: | ICOS Corporation (Indianapolis, IN) |
Application Number: | 13/730,276 |
Patent Claim Types: see list of patent claims | Use; Device; |
Drugs Protected by US Patent RE44599
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-001 | Jul 23, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA | ⤷ Try a Trial | ||||
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-001 | Jul 23, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL | ⤷ Try a Trial | ||||
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-002 | Jul 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL | ⤷ Try a Trial | ||||
Gilead Sciences Inc | ZYDELIG | idelalisib | TABLET;ORAL | 205858-002 | Jul 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE44599
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2005245875 | ⤷ Try a Trial | |||
Australia | 2009230739 | ⤷ Try a Trial | |||
Canada | 2566609 | ⤷ Try a Trial | |||
China | 101031569 | ⤷ Try a Trial | |||
China | 102229609 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |